Phase II Trial of Doxil, Vincristine and Decadron in Multiple Myeloma
OBJECTIVES: I. Assess the response rate and duration of response of multiple myeloma treated
with doxorubicin HCl liposome, vincristine, and dexamethasone. II. Define the qualitative
and quantitative toxic effects of this regimen in these patients.
OUTLINE: Patients are stratified into newly diagnosed (group A) and previously treated
(group B) patients. Patients receive doxorubicin HCl liposome IV over 2.5 hours, followed by
vincristine by bolus IV over 5 minutes on day 1. Dexamethasone is administered orally or by
IV on days 1-4. Treatment is repeated every 4 weeks for a minimum of 6 courses, and 2
courses after maximum response unless unacceptable toxic effects or disease progression
occur. Patients are followed until death.
PROJECTED ACCRUAL: A maximum of 33 patients from group A and 34 patients from group B will
be accrued for this study within 6-14 months.
Primary Purpose: Treatment
Mohamad A. Hussein, MD
The Cleveland Clinic
United States: Federal Government
|Cleveland Clinic Taussig Cancer Center||Cleveland, Ohio 44195|